Tonix Pharmaceuticals Stock Soars After $25M Buyback Boost: Retail Traders See 'Blueprint for Rerating'

Tonix Pharmaceuticals stock surged into retail spotlight after expanding its share repurchase authorization by $25M, bringing the total to $35M. Retail traders see this as a sign of management confidence and a potential catalyst for renewed valuation upside. The commercial rollout of Tonmya and buyback progress strengthened bullish sentiment around the company's turnaround. Some users speculated that the larger repurchase program could pressure short sellers or hint at early buyout interest.